Wave Life Sciences (NASDAQ:WVE) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Tuesday.

Several other brokerages also recently commented on WVE. HC Wainwright set a $49.00 price objective on Wave Life Sciences and gave the stock a “buy” rating in a research note on Monday, November 12th. Leerink Swann started coverage on Wave Life Sciences in a research note on Tuesday, November 27th. They issued an “outperform” rating and a $61.00 price target on the stock. Stifel Nicolaus started coverage on Wave Life Sciences in a research note on Monday, August 6th. They issued a “buy” rating and a $56.00 price target on the stock. Finally, Mizuho set a $65.00 price target on Wave Life Sciences and gave the company a “buy” rating in a research note on Thursday, August 9th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $58.20.

Shares of Wave Life Sciences stock opened at $46.83 on Tuesday. The firm has a market cap of $1.41 billion, a P/E ratio of -12.16 and a beta of 1.09. Wave Life Sciences has a 12 month low of $31.65 and a 12 month high of $56.00. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.85 and a current ratio of 1.85.

Wave Life Sciences (NASDAQ:WVE) last issued its quarterly earnings data on Friday, November 9th. The company reported ($1.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.26) by ($0.02). The business had revenue of $4.49 million for the quarter, compared to analyst estimates of $5.36 million. Wave Life Sciences had a negative return on equity of 112.13% and a negative net margin of 1,114.49%. On average, analysts expect that Wave Life Sciences will post -5 EPS for the current year.

In other Wave Life Sciences news, VP Chandra Vargeese sold 3,000 shares of Wave Life Sciences stock in a transaction dated Monday, September 24th. The stock was sold at an average price of $55.00, for a total value of $165,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Keith Regnante sold 29,500 shares of Wave Life Sciences stock in a transaction dated Monday, September 24th. The shares were sold at an average price of $55.00, for a total value of $1,622,500.00. The disclosure for this sale can be found here. Insiders sold a total of 59,075 shares of company stock worth $3,018,600 in the last three months. Company insiders own 44.20% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Strs Ohio acquired a new stake in shares of Wave Life Sciences in the third quarter valued at about $140,000. United Services Automobile Association acquired a new stake in shares of Wave Life Sciences in the third quarter valued at about $204,000. Putnam Investments LLC acquired a new stake in shares of Wave Life Sciences in the third quarter valued at about $207,000. Jane Street Group LLC acquired a new stake in shares of Wave Life Sciences in the third quarter valued at about $210,000. Finally, Man Group plc acquired a new stake in shares of Wave Life Sciences in the third quarter valued at about $287,000. 80.78% of the stock is currently owned by institutional investors and hedge funds.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Further Reading: Why is insider trading harmful?

Analyst Recommendations for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.